Cite
Lonardi S, Sobrero A, Rosati G, et al. Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial. Ann Oncol. 2017;28(12):3110doi: 10.1093/annonc/mdx021.
Lonardi, S., Sobrero, A., Rosati, G., Di Bartolomeo, M., Ronzoni, M., Aprile, G., Massida, B., Scartozzi, M., Banzi, M., Zampino, M. G., Pasini, F., Marchetti, P., Cantore, M., Zaniboni, A., Rimassa, L., Ciuffreda, L., Ferrari, D., Barni, S., Zagonel, V., Maiello, E., Rulli, E., Labianca, R. (2017). Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial. Annals of oncology : official journal of the European Society for Medical Oncology, 28(12), 3110. https://doi.org/10.1093/annonc/mdx021
Lonardi, S, et al. "Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial." Annals of oncology : official journal of the European Society for Medical Oncology vol. 28,12 (2017): 3110. doi: https://doi.org/10.1093/annonc/mdx021
Lonardi S, Sobrero A, Rosati G, Di Bartolomeo M, Ronzoni M, Aprile G, Massida B, Scartozzi M, Banzi M, Zampino MG, Pasini F, Marchetti P, Cantore M, Zaniboni A, Rimassa L, Ciuffreda L, Ferrari D, Barni S, Zagonel V, Maiello E, Rulli E, Labianca R. Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial. Ann Oncol. 2017 Dec 01;28(12):3110. doi: 10.1093/annonc/mdx021. PMID: 28327986.
Copy
Download .nbib
